Falkenbach, F.; Ambrosini, F.; Tennstedt, P.; Eiber, M.; Heck, M.M.; Preisser, F.; Graefen, M.; Budäus, L.; Koehler, D.; Knipper, S.;
et al. EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer. Cancers 2023, 15, 5008.
https://doi.org/10.3390/cancers15205008
AMA Style
Falkenbach F, Ambrosini F, Tennstedt P, Eiber M, Heck MM, Preisser F, Graefen M, Budäus L, Koehler D, Knipper S,
et al. EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer. Cancers. 2023; 15(20):5008.
https://doi.org/10.3390/cancers15205008
Chicago/Turabian Style
Falkenbach, Fabian, Francesca Ambrosini, Pierre Tennstedt, Matthias Eiber, Matthias M. Heck, Felix Preisser, Markus Graefen, Lars Budäus, Daniel Koehler, Sophie Knipper,
and et al. 2023. "EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer" Cancers 15, no. 20: 5008.
https://doi.org/10.3390/cancers15205008
APA Style
Falkenbach, F., Ambrosini, F., Tennstedt, P., Eiber, M., Heck, M. M., Preisser, F., Graefen, M., Budäus, L., Koehler, D., Knipper, S., & Maurer, T.
(2023). EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer. Cancers, 15(20), 5008.
https://doi.org/10.3390/cancers15205008
